9MW 3811
Alternative Names: 9MW-3811Latest Information Update: 12 Sep 2025
At a glance
- Originator Mabwell (Shanghai) Bioscience
- Class Antifibrotics; Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Interleukin 11 inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Autoimmune disorders; Hypertrophic scars; Idiopathic pulmonary fibrosis; Pulmonary fibrosis; Solid tumours
Most Recent Events
- 12 Sep 2025 Phase-I clinical trials in Hypertrophic scars in China (unspecified route)(Mabwell Bioscience pipeline, August 2025)
- 12 Sep 2025 Phase-I clinical trials in Idiopathic pulmonary fibrosis in USA (Parenteral) (Mabwell Bioscience pipeline, August 2025)
- 26 Jun 2025 9MW 3811 licensed to Calico worldwide, excluding Hong Kong, Macau, Taiwan and China